Advertisement
JOGC

Committee Opinion No. 418: The Complete 11–14 Week Prenatal Sonographic Examination

      ABSTRACT

      Objective

      Sonography during the first trimester provides an opportunity to assess a pregnancy in its early stage. This document provides an opinion about the implementation and content of prenatal sonographic examinations at 11–14 weeks gestation in Canada.

      Target population

      Pregnant women at 11–14 weeks gestation.

      Benefits, harms, and costs

      The 11–14 week prenatal sonographic examination can provide important information that may contribute to pregnancy management. It can be used to confirm viability, establish gestational age, determine the number of fetuses, assess the adnexa/ovaries, and, in a multiple pregnancy, assess chorionicity and amnionicity. Scanning also offers an opportunity to detect fetal abnormalities and perform aneuploidy screening by measuring the nuchal translucency thickness. It may be valuable in screening for preeclampsia and other obstetrical disorders (by combining uterine artery Doppler scanning with other bio-clinical markers) and for invasive placentation. There are no physical harms to mother or fetus from offering a routine 11–14 week prenatal sonographic examination, and there are no extra costs for patients.

      Evidence

      Articles related to routine 11–14 week prenatal sonography were identified in a search of EMBASE and MEDLINE using the search terms first trimester ultrasound, nuchal translucency, and 11–14 week ultrasound. The search included all articles published on the topic until May 2019. Abstracts were reviewed by one author, and articles deemed relevant were then reviewed in full to determine whether to include them in the study. Articles that were not in English and articles that did not pertain to 11–14 week prenatal sonography were excluded.

      Intended audience

      This document is intended for sonographers, midwives, family physicians, obstetricians, and maternal–fetal medicine specialists.

      Keywords

      Abbreviations:

      CRL (crown–rump length), NT (nuchal translucency), PI (pulsatility index), SGA (small for gestational age)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Salomon LJ
        • Alfirevic Z
        • Bilardo CM
        • et al.
        ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan.
        Ultrasound Obstet Gynecol. 2013; 41: 102-113
      1. AIUM-ACR-ACOG-SMFM-SRU practice parameter for the performance of standard diagnostic obstetric ultrasound examinations.
        J Ultrasound Med. 2018; 37: E13-E24
      2. The Fetal Medicine Foundation. Certificates of competency: nuchal translucency scan. Available at: https://fetalmedicine.org/fmf-certification/certificates-of-competence/nuchal-translucency-scan. Accessed on April 14, 2020.

      3. Fong K, Levi C, Mayer L, et al. CAR standard for performing diagnostic obstetric ultrasound examinations. Available at: https://car.ca/wp-content/uploads/Ultrasound-Performing-Diagnostic-Obstetric-Ultrasound-Examinations-2010.pdf. Accessed on January 15, 2021.

      4. WFUMB/ISUOG statement on the safe use of doppler ultrasound during 11-14 week scans (or earlier in pregnancy).
        Ultrasound Med Biol. 2013; 39: 373
      5. American Institute of Ultrasound in Medicine. AIUM official statement: as low as reasonably achievable (ALARA) principle. Available at: https://www.aium.org/officialStatements/39. Accessed on April 17, 2020.

        • Grangé G
        • Althuser M
        • Fresson J
        • et al.
        Semi-automated adjusted measurement of nuchal translucency: feasibility and reproducibility.
        Ultrasound Obstet Gynecol. 2011; 37: 335-340
        • Bakker M
        • Mulder P
        • Birnie E
        • et al.
        Intra-operator and inter-operator reliability of manual and semiautomated measurement of fetal nuchal translucency: a cross sectional study.
        Prenat Diagn. 2013; 33: 1264-1271
        • Butt K
        • Lim KI.
        Guideline No. 388-determination of gestational age by ultrasound.
        J Obstet Gynaecol Canada. 2019; 41: 1497-1507
      6. Committee Opinion No. 688: Management of suboptimally dated pregnancies.
        Obstet Gynecol. 2017; 129: 29-32
      7. Methods for estimating the due date. Committee opinion 700.
        Obstet Gynecol. 2017; 129: 959-960
        • Snijders RJM
        • Noble P
        • Sebire N
        • et al.
        UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation.
        Lancet. 1998; 352: 343-346
        • Cicero S
        • Rembouskos G
        • Vandecruys H
        • et al.
        Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan.
        Ultrasound Obstet Gynecol. 2004; 23: 218-223
        • Borrell A
        • Martinez JM
        • Serés A
        • et al.
        Ductus venosus assessment at the time of nuchal translucency measurement in the detection of fetal aneuploidy.
        Prenat Diagn. 2003; 23: 921-926
        • Matias A
        • Gomes C
        • Flack N
        • et al.
        Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow.
        Ultrasound Obstet Gynecol. 1998; 12: 380-384
        • Kagan KO
        • Valencia C
        • Livanos P
        • et al.
        Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation.
        Ultrasound Obstet Gynecol. 2009; 33: 18-22
        • Goldstein I
        • Weizman B
        • Nizar K
        • et al.
        The nuchal translucency examination leading to early diagnosis of structural fetal anomalies.
        Early Hum Dev. 2014; 90: 87-91
        • Karim JN
        • Roberts NW
        • Salomon LJ
        • et al.
        Systematic review of first-trimester ultrasound screening for detection of fetal structural anomalies and factors that affect screening performance.
        Ultrasound Obstet Gynecol. 2017; 50: 429-441
        • Syngelaki A
        • Hammami A
        • Bower S
        • et al.
        Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11–13 weeks’ gestation.
        Ultrasound Obstet Gynecol. 2019; 54: 468-476
        • Kenkhuis MJA
        • Bakker M
        • Bardi F
        • et al.
        Effectiveness of 12–13-week scan for early diagnosis of fetal congenital anomalies in the cell-free DNA era.
        Ultrasound Obstet Gynecol. 2018; 51: 463-469
        • Korenromp MJ
        • Christiaens GCML
        • Van Den Bout J
        • et al.
        Long-term psychological consequences of pregnancy termination for fetal abnormality: a cross-sectional study.
        Prenat Diagn. 2005; 25: 253-260
        • Iliescu D
        • Tudorache S
        • Comanescu A
        • et al.
        Improved detection rate of structural abnormalities in the first trimester using an extended examination protocol.
        Ultrasound Obstet Gynecol. 2013; 42: 300-309
        • Springhall EA
        • Rolnik DL
        • Reddy M
        • et al.
        How to perform a sonographic morphological assessment of the fetus at 11-14 weeks of gestation.
        Australas J Ultrasound Med. 2018; 21: 125-137
        • Edwards L
        • Hui L.
        First and second trimester screening for fetal structural anomalies.
        Semin Fetal Neonatal Med. 2018; 23: 102-111
        • Litwinska E
        • Syngelaki A
        • Cimpoca B
        • et al.
        Outcome of twin pregnancy with two live fetuses at 11–13 weeks’ gestation.
        Ultrasound Obstet Gynecol. 2020; 55: 32-38
        • Bhide A
        • Sankaran S
        • Sairam S
        • et al.
        Relationship of intertwin crown-rump length discrepancy to chorionicity, fetal demise and birth-weight discordance.
        Ultrasound Obstet Gynecol. 2009; 34: 131-135
        • Harper LM
        • Roehl KA
        • Odibo AO
        • et al.
        First-trimester growth discordance and adverse pregnancy outcome in dichorionic twins.
        Ultrasound Obstet Gynecol. 2013; 41: 627-631
        • Dias T
        • Arcangeli T
        • Bhide A
        • et al.
        First-trimester ultrasound determination of chorionicity in twin pregnancy.
        Ultrasound Obstet Gynecol. 2011; 38: 530-532
        • Maruotti GM
        • Saccone G
        • Morlando M
        • et al.
        First-trimester ultrasound determination of chorionicity in twin gestations using the lambda sign: a systematic review and meta-analysis.
        Eur J Obstet Gynecol Reprod Biol. 2016; 202: 66-70
        • Chasen ST
        • Perni SC
        • Kalish RB
        • et al.
        First-trimester risk assessment for trisomies 21 and 18 in twin pregnancy.
        Am J Obstet Gynecol. 2007; 197 (374 e1-3)
        • Spencer K
        • Staboulidou I
        • Nicolaides KH.
        First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
        Prenat Diagn. 2010; 30: 235-240
        • Magee LA
        • Pels A
        • Helewa M
        • et al.
        Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary.
        J Obstet Gynaecol Canada. 2014; 36: 416-438
        • Plasencia W
        • Maiz N
        • Bonino S
        • et al.
        Uterine artery Doppler at 11 + 0 to 13 + 6 weeks inthe prediction of pre-eclampsia.
        Ultrasound Obstet Gynecol. 2007; 30: 742-749
        • Rolnik DL
        • Wright D
        • Poon LCY
        • et al.
        Aspirin versus Placebo in pregnancies at high risk for preterm preeclampsia.
        N Engl J Med. 2017; 377: 613-622
        • Martin A
        • Bindra R
        • Curcio P
        • et al.
        Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11–14 weeks of gestation.
        Ultrasound Obstet Gynecol. 2001; 18: 583-586
        • Velauthar L
        • Plana MN
        • Kalidindi M
        • et al.
        First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55 974 women.
        Ultrasound Obstet Gynecol. 2014; 43: 500-507
        • Poon LCY
        • Karagiannis G
        • Leal A
        • et al.
        Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks.
        Ultrasound Obstet Gynecol. 2009; 34: 497-502
        • Akolekar R
        • Syngelaki A
        • Poon L
        • et al.
        Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
        Fetal Diagn Ther. 2013; 33: 8-15
        • Poon LCY
        • Syngelaki A
        • Akolekar R
        • et al.
        Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
        Fetal Diagn Ther. 2013; 33: 16-27
        • Cali G
        • Forlani F
        • Foti F
        • et al.
        Diagnostic accuracy of first-trimester ultrasound in detecting abnormally invasive placenta in high-risk women with placenta previa.
        Ultrasound Obstet Gynecol. 2018; 52: 258-264
        • Panaiotova J
        • Tokunaka M
        • Krajewska K
        • et al.
        Screening for morbidly adherent placenta in early pregnancy.
        Ultrasound Obstet Gynecol. 2019; 53: 101-106
        • Hobson SR
        • Kingdom JC
        • Murji A
        • et al.
        No. 383-screening, diagnosis, and management of placenta accreta spectrum disorders.
        J Obstet Gynaecol Canada. 2019; 41: 1035-1049
        • Carvalho MHB
        • Bittar RE
        • Brizot ML
        • et al.
        Cervical length at 11-14 weeks ’ and 22-24 weeks’ gestation evaluated by transvaginal sonography, and gestational age at delivery.
        Ultrasound Obstet Gynecol. 2003; 21: 135-139
        • Peixoto AB
        • Caldas TMR da C
        • Barros JJA
        • et al.
        Reference ranges for the uterine arteries Doppler and cervical length measurement at 11–13(+6) weeks of gestation in a Brazilian population.
        J Matern Neonatal Med. 2016; 29: 2909-2914
        • Wulff CB
        • Rode L
        • Rosthøj S
        • et al.
        Transvaginal sonographic cervical length in first and second trimesters in a low-risk population: a prospective study.
        Ultrasound Obstet Gynecol. 2018; 51: 604-613
        • Antsaklis P
        • Daskalakis G
        • Pilalis A
        • et al.
        The role of cervical length measurement at 11-14 weeks for the prediction of preterm delivery.
        J Matern Neonatal Med. 2011; 24: 465-470
        • Greco E
        • Lange A
        • Ushakov F
        • et al.
        Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks.
        Prenat Diagn. 2011; 31: 84-89
        • Schwartz N
        • Timor-Tritsch IE
        • Wang E
        Adnexal masses in pregnancy.
        Clin Obstet Gynecol. 2009; 52: 570-585
        • Yazbek J
        • Salim R
        • Woelfer B
        • et al.
        The value of ultrasound visualization of the ovaries during the routine 11-14 weeks nuchal translucency scan.
        Eur J Obstet Gynecol Reprod Biol. 2007; 132: 154-158
        • Cavaco-Gomes J
        • Jorge Moreira C
        • Rocha A
        • et al.
        Investigation and management of adnexal masses in pregnancy.
        Scientifica (Cairo). 2016; 2016